ABT vs MDT — Key Metrics
| Metric | ABT (ABBOTT LABORATORIES) | MDT (MEDTRONIC PLC) |
|---|---|---|
| Price | 104.48 | 100.72 |
| Market Cap | 180.95 Billion | 128.83 Billion |
| P/E (TTM) | 38.84 | 24.63 |
| P/B (Quarterly) | 3.875 | 2.371 |
| P/S (TTM) | 3.75 | 3.43 |
| Net Profit Margin (TTM) | 9.7 | 13.9 |
| Gross Margin (TTM) | 56.9 | 65.0 |
| ROE (TTM) | 9.0 | 10.6 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Underperform
Outperform
Recommendation Summary
Stock ABT is projected to underperform the market, stock MDT is projected to outperform the market. Upfront Recommendation: MDT.
Financial Metrics
| ABT | Metrics | MDT |
|---|---|---|
| $104.48 | Price | $100.72 |
| — | Market Capitalization | — |
| 38.84 | Price to Earnings Ratio | 24.63 |
| 3.75 | Price to Sales | 3.43 |
| 26.78 | Price to FCF Ratio | 21.01 |
| 6.59 | Price to Gross Profit | 5.28 |
| 54.6 | Price to R&D | 44.15 |
| 7.7 | Price to Current Assets | 5.28 |
ABT vs MDT at a glance
Abbott Laboratories (ABT) and Medtronic PLC (MDT) are both Medical Devices companies in the Healthcare sector. ABT is the larger, at $181.0 billion in market value against $128.8 billion for MDT, about 1.4 times the size.
On trailing-twelve-month figures, ABT trades at 38.8 times trailing earnings and MDT at 24.6; net profit margins are 9.7% and 13.9%.
The Upfront Investment model currently rates ABT Underperform and MDT Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.